scholarly article | Q13442814 |
P356 | DOI | 10.1093/JAC/DKV322 |
P698 | PubMed publication ID | 26503666 |
P50 | author | Praveen Papareddy | Q58658896 |
Ravi K V Bhongir | Q85276206 | ||
P2093 | author name string | Artur Schmidtchen | |
Martin Malmsten | |||
Matthias Mörgelin | |||
Martina Kalle | |||
Gopinath Kasetty | |||
P2860 | cites work | Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis | Q27331817 |
Responses of Pseudomonas aeruginosa to antimicrobials | Q28305587 | ||
Highly selective end-tagged antimicrobial peptides derived from PRELP | Q28476835 | ||
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 | ||
Proteolysis of human thrombin generates novel host defense peptides | Q29871443 | ||
High-throughput generation of small antibacterial peptides with improved activity | Q33220258 | ||
Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa | Q33293383 | ||
A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. | Q33927961 | ||
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances | Q34750112 | ||
Antithrombin: a new look at the actions of a serine protease inhibitor | Q35004303 | ||
The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. | Q35067228 | ||
Antibacterial peptides for therapeutic use: obstacles and realistic outlook | Q36556909 | ||
Proteolytic activation transforms heparin cofactor II into a host defense molecule | Q36914757 | ||
Host-pathogen interactions in sepsis | Q37026360 | ||
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells | Q37628594 | ||
Activation of the complement system generates antibacterial peptides | Q37695583 | ||
Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. | Q37984505 | ||
Modulating immunity as a therapy for bacterial infections | Q37994068 | ||
Cationic host defence peptides: multifaceted role in immune modulation and inflammation. | Q38022156 | ||
Sepsis and thrombosis | Q38102642 | ||
Immune modulation by multifaceted cationic host defense (antimicrobial) peptides | Q38162670 | ||
New perspectives in the management of Pseudomonas aeruginosa infections | Q38243221 | ||
Importance of lipopolysaccharide aggregate disruption for the anti-endotoxic effects of heparin cofactor II peptides | Q39134176 | ||
P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients | Q39479122 | ||
Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure | Q40407531 | ||
Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group | Q40638967 | ||
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group | Q40653300 | ||
Antimicrobial effects of helix D-derived peptides of human antithrombin III | Q41747279 | ||
Antibacterial agents based on the cyclic D,L-alpha-peptide architecture | Q44022306 | ||
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group | Q44267568 | ||
Antimicrobial activities of heparin-binding peptides | Q44629787 | ||
Ultrasensitive assays for endogenous antimicrobial polypeptides | Q45416239 | ||
Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach | Q46438108 | ||
Domain 5 of high molecular weight kininogen is antibacterial | Q46642869 | ||
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections | Q46726010 | ||
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group | Q46886444 | ||
Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. | Q47831006 | ||
Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. | Q53753081 | ||
Antimicrobial peptides derived from growth factors. | Q54442631 | ||
Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. | Q54464584 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
antimicrobial peptide | Q1201508 | ||
P304 | page(s) | 170-180 | |
P577 | publication date | 2015-10-26 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection | |
P478 | volume | 71 |